Delivery Order SPE2DB20D6037-SPE2DB24FTWE9

Award Date 7/19/24
Potential Completion Date 7/22/24
Potential Value $8.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is valued at $1,001.76 and has an ultimate completion date of May 10, 2024. The contract is for the delivery of MOVIPREP powder packets, a pharmaceutical product, to support the recurring medical supply needs of military health facilities worldwide. This delivery order is part of a larger indefinite...
This is a delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA). The $1,068.30 firm fixed-price contract is for the delivery of MOVIPREP POWDER PACKETS, with a completion date of June 12, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the DLA to issue delivery orders for a comprehensive range of...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $2,781.90 contract is for the delivery of MOVIPREP POWDER PACKETS to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders for a...
This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA). The $1,068.96 contract is for the supply of MOVIPREP powder packets, a pharmaceutical product. The delivery order was issued under DMS Pharmaceutical Group's $499,999,999 indefinite delivery contract with the DLA, which allows the agency to place orders for a comprehensive range of pharmaceutical items to support the...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $1,230.97, is for the supply of MOVIPREP powder packets to support the recurring medical supply needs of military health facilities. DMS Pharmaceutical Group holds a larger $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to...
This is a federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is a $1,314.06 firm fixed-price delivery order for the supply of MOVIPREP powder packets, a specialized pharmaceutical product, with a completion date of June 26, 2024. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $1,505.84 contract is to provide MOVIPREP powder packets, a medication used for bowel preparation procedures. The award is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. This IDC allows the DLA to issue delivery orders for a...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of MOVIPREP POWDER PACKETS, a medical product, with a ceiling value of $1,318.80 and a performance period ending on April 16, 2025. The contract is not set aside and was awarded as a firm-fixed-price delivery order. Amerisourcebergen Drug Corp is the prime contractor and is...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,533.27, is a delivery order for MOVIPREP powder packets. The contract has an ultimate completion date of October 13, 2023 and is a firm fixed-price type. This award is associated with a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued...
This federal contract award, valued at $2,943.22, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order (SPE2DB25FSUZJ) for the supply of 4,568,072,824 units of MOVIPREP POWDER PACKETS. The contract has a firm fixed price and an ultimate completion date of April 30, 2025. Amerisourcebergen Drug Corp also holds a substantial Indefinite Delivery Contract (IDC) with the DLA...
  • SPE2DB20D6037
    Indefinite Delivery Contract
  • SPE2DB20D6037-SPE2DB24FTWE9
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $8,201.57, is for the supply of MOVIPREP POWDER PACKETS, a specialized pharmaceutical product. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA, valued at $499,999,999 and valid through November 2026. The IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide. This contract does not have a set-aside designation.

Generated 5/17/25, 9:56 AM